Miscellaneous Urologenital Disorders
Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which has been found to delay the progression of an autosomal dominant form of polycystic kidney disease.
The risk for premature death increased by 62% and 42% for stage 3 CKD patients with vitamin D deficiency and elevated parathyroid hormone levels, respectively.
Based on one retrospective review of 8 years of compliance, the strongest predictors of shorter length of stay were identified as no nasogastric tube, early mobilization, early oral nutrition, early removal of epidural and urinary catheter, and nonopioid analgesia.
Relative to patients without CKD or preventable HAC, the odds ratios for mortality during index hospitalization were 2.22, 5.26, and 9.56, respectively, for patients with CKD with no HAC, without CKD with HACs, and with CKD and HACs.
After starting CPAP, nighttime urination was reduced in 65% patients who had to get up more than once during the night to urinate.
In a clinical practice guideline published online January 16 in the Journal of Clinical Oncology, recommendations are presented for the management of patients with small renal masses (SRMs).
Diabetes-related end-stage renal disease among Native American adults fell by more than half over almost 20 years, according to research published in the January 10 early-release issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
For kidney transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 infection, treatment with ledipasvir-sofosbuvir for 12 or 24 weeks is safe and efficacious.
There is no connection between vasectomy and overall risk of prostate cancer or prostate cancer mortality, according to a study published online September 19 in the Journal of Clinical Oncology.